Lv2
196 积分 2025-03-06 加入
Bispecific T-cell engagers in autoimmune diseases: mechanisms of action, clinical evidence challenges, and therapeutic perspectives
1个月前
已完结
Chimeric antigen receptor-based cellular therapy in autoimmune diseases: A systematic review and meta-analysis of clinical, serological and safety outcomes
1个月前
已完结
Nerandomilast in Patients with Progressive Pulmonary Fibrosis
1个月前
已完结
Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial
7个月前
已完结
Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial
7个月前
已完结
Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis–Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial
7个月前
已完结
OP0295 RITUXIMAB VERSUS TOCILIZUMAB IN PATIENTS WITH SYSTEMIC SCLEROSIS: 52-WEEK OUTCOMES OF A STRATIFIED BIOPSY-DRIVEN, OPEN-LABEL, RANDOMIZED CONTROLLED TRIAL
7个月前
已完结
ABS0514 EFFICACY AND SAFETY OF TOCILIZUMAB IN SYSTEMIC SCLEROSIS: A RETROSPECTIVE, MONOCENTRIC STUDY
8个月前
已关闭
POS0652 SAFETY AND EFFICACY OF TOCILIZUMAB IN SYSTEMIC SCLEROSIS: A MULTICENTER FRENCH-ITALIAN RETROSPECTIVE STUDY
8个月前
已关闭
P153 Rituximab and tocilizumab and their effect on lung disease progression in scleroderma: a retrospective cohort study at a single centre
8个月前
已关闭
皖公网安备34019202002308
